Newsbreak Confirmed: What to make of Cipla's Yurpeak pact with Eli Lilly? Nuvama raises target by Rs 74
Published on 24/10/2025 10:36 AM
Cipla Ltd and Eli Lilly and Company (India) Private Ltd have entered into a marketing and distribution agreement for the launch of the second brand of tirzepatide in India under the name 'Yurpeak'. As of 10 am, Cipla's stock was trading in red at Rs 1,603 apiece, down by 2.53 per cent.
The confirmation of the marketing and distribution agreement comes after Zee Business reported that both firms were in talks for the anti-diabetic medications deal on August 25.
As per the new agreement, Cipla will handle the distribution and marketing of the diabetes drug, 'Yurpeak', all over India, while Eli Lilly will take care of the manufacturing and supply of the product.
'Yurpeak' will become the second brand of tirzepatide in the Indian market, the first being Lilly's own brand 'Mounjaro'.
The deal is expected to expand the scope of treatment for type 2 diabetes and obesity in India.
According to the company's release, tirzepatide is a prescription-based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicated as an adjunct to diet and exercise for the treatment of type 2 diabetes and chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity.
"Yurpeak® (tirzepatide) will be available in the KwikPen® presentation, a multi-dose single-patient-use prefilled pen," the release read.
The companies have declared that the pricing for Yurpeak will be equal to that of Mounjaro, which is now selling in the price range of Rs 13,000 to Rs 26,000 per month.
Eli Lilly's launch of Mounjaro in India in March 2025 was the first step of Tirzepatide in the country. In June 2025, the company received the green light to bring in the KwikPen version, a pre-filled injection pen that allows easier administration, thus releasing a new product.
For the past two months, Mounjaro recorded sales of more than Rs 100 crore a month.
Nuvama has maintained a 'hold' rating on Cipla's stock and has upgraded the target price from Rs 1,651 to Rs 1,725, translating to an increase of Rs 74.
The brokerage firm stated that the deal will give Cipla entry into the injectable GLP-1 segment.
Nuvama expects that the company can generate revenue of Rs 360 crore in FY26 and Rs 370 crore in FY27 from the sale of Yurpeak.